Breaking News, Collaborations & Alliances

Genmab Achieves $3M Janssen Milestone

Advances DuoBody candidate targeting cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has reached a milestone in its collaboration with Janssen Biotech, triggering a $3 million milestone payment for preclinical progress with a DuoBody product candidate targeting cancer. To date, Janssen has optioned 11 programs out of 20 under the bispecific DuoBody platform collaboration with Genmab. Genmab currently has five commercial partnerships for its DuoBody technology. “This milestone is another step in the continued validation of our DuoBody technology. Our technology c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters